Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators

Cell Chemical Biology

Volumn 24, Issue 7, 2017, Pages 858-869.e5

  Shah, Falgun ^a,c   Stepan, Antonia F ^a   O'Mahony, Alison ^b   Velichko, Sharlene ^b   Folias, Alexandra E ^b   Houle, Christopher ^a   Shaffer, Christopher L ^a   Marcek, John ^a   Whritenour, Jessica ^a   Stanton, Robert ^a   Berg, Ellen L ^b  

^a PFIZER INC   (United States)

^b Bioseek Inc   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

adverse outcome pathway; aryl hydrocarbon receptor; immune reaction; mGluR5 NAMs; molecular initiating events; primary human cells; skin hypersensitivity

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; METABOTROPIC RECEPTOR 5; PROSTAGLANDIN E2; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TUMOR NECROSIS FACTOR; AROMATIC HYDROCARBON RECEPTOR; CALCITRIOL RECEPTOR; LIPOPOLYSACCHARIDE; PROTEIN BINDING;

ALLOSTERISM; ARTICLE; B LYMPHOCYTE ACTIVATION; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; KERATINOCYTE; MACROPHAGE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY CELL CULTURE; PRIORITY JOURNAL; SKIN FIBROBLAST; SKIN TOXICITY; T LYMPHOCYTE; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICAL DATABASE; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; FIBROBLAST; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; SKIN DISEASE; TOXICITY;

ALLOSTERIC REGULATION; CELLS, CULTURED; DATABASES, CHEMICAL; DINOPROSTONE; DOWN-REGULATION; FIBROBLASTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; PROTEIN BINDING; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, CALCITRIOL; RECEPTORS, RETINOIC ACID; SKIN DISEASES; SMALL MOLECULE LIBRARIES; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 85021363075     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.06.003     Document Type: Article

References (69)

1. Acosta-Rodriguez, E.V., Napolitani, G., Lanzavecchia, A., Sallusto, F., Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8 (2007), 942–949.
2. Ahmed, S.A., Gogal, R.M. Jr., Walsh, J.E., A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J. Immunol. Methods 170 (1994), 211–224.
3. Baier, G., Wagner, J., PKC inhibitors: potential in T cell-dependent immune diseases. Curr. Opin. Cell Biol. 21 (2009), 262–267.
4. Berg, E.L., Phenotypic chemical biology for predicting safety and efficacy. Drug Discov. Today Technol., 2017, 10.1016/j.ddtec.2017.01.001.
5. Berg, E.L., Kunkel, E.J., Hytopoulos, E., Plavec, I., Characterization of compound mechanisms and secondary activities by BioMAP analysis. J. Pharmacol. Toxicol. Methods 53 (2006), 67–74.
6. Berg, E.L., Yang, J., Melrose, J., Nguyen, D., Privat, S., Rosler, E., Kunkel, E.J., Ekins, S., Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J. Pharmacol. Toxicol. Methods 61 (2010), 3–15.
7. Berg, E.L., Yang, J., Polokoff, M.A., Building predictive models for mechanism-of-action classification from phenotypic assay data sets. J. Biomol. Screen. 18 (2013), 1260–1269.
8. Bergamini, G., Bell, K., Shimamura, S., Werner, T., Cansfield, A., Muller, K., Perrin, J., Rau, C., Ellard, K., Hopf, C., et al. A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation. Nat. Chem. Biol. 8 (2012), 576–582.
9. Bigby, M., Rates of cutaneous reactions to drugs. Arch. Dermatol. 137 (2001), 765–770.
10. Bowes, J., Brown, A.J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., Whitebread, S., Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11 (2012), 909–922.
11. Bruner, C.R., Feldman, S.R., Ventrapragada, M., Fleischer, A.B. Jr., A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol. Online J., 9, 2003, 2.
12. Clapp, K., Novartis Clinical Trials in Fragile X Ended. 2014 https://www.fraxa.org/novartis-discontinues-development-mavoglurant-afq056-fragile-x-syndrome/.
13. Desallais, L., Bouchez, C., Mouhsine, H., Moreau, G., Ratsimandresy, R., Montes, M., Do, H., Quintin-Colonna, F., Zagury, J.F., Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the delayed-type hypersensitivity reaction in cynomolgus monkeys. Sci. Rep., 6, 2016, 19549.
14. Dienz, O., Rincon, M., The effects of IL-6 on CD4 T cell responses. Clin. Immunol. 130 (2009), 27–33.
15. Ekins, S., Mirny, L., Schuetz, E.G., A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. Pharm. Res. 19 (2002), 1788–1800.
16. Emmitte, K.A., mGlu5 negative allosteric modulators: a patent review (2010-2012). Expert Opin. Ther. Pat. 23 (2013), 393–408.
17. Esser, C., The aryl hydrocarbon receptor in immunity: tools and potential. Methods Mol. Biol. 1371 (2016), 239–257.
18. Esser, C., Rannug, A., The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol. Rev. 67 (2015), 259–279.
19. Esser, C., Bargen, I., Weighardt, H., Haarmann-Stemmann, T., Krutmann, J., Functions of the aryl hydrocarbon receptor in the skin. Semin. Immunopathol. 35 (2013), 677–691.
20. Fazio, F., Lionetto, L., Curto, M., Iacovelli, L., Copeland, C.S., Neale, S.A., Bruno, V., Battaglia, G., Salt, T.E., Nicoletti, F., Cinnabarinic acid and xanthurenic acid: two kynurenine metabolites that interact with metabotropic glutamate receptors. Neuropharmacology 112 (2017), 365–372.
21. Furue, M., Takahara, M., Nakahara, T., Uchi, H., Role of AhR/ARNT system in skin homeostasis. Arch. Dermatol. Res. 306 (2014), 769–779.
22. Fuxe, K., Borroto-Escuela, D.O., Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin. Investig. Drugs 24 (2015), 1247–1260.
23. Gagliani, N., Amezcua Vesely, M.C., Iseppon, A., Brockmann, L., Xu, H., Palm, N.W., de Zoete, M.R., Licona-Limon, P., Paiva, R.S., Ching, T., et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523 (2015), 221–225.
24. Gerstenberger, B.S., Trzupek, J.D., Tallant, C., Fedorov, O., Filippakopoulos, P., Brennan, P.E., Fedele, V., Martin, S., Picaud, S., Rogers, C., et al. Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit. J. Med. Chem. 59 (2016), 4800–4811.
25. Greene, N., Song, M., Predicting in vivo safety characteristics using physiochemical properties and in vitro assays. Future Med. Chem. 3 (2011), 1503–1511.
26. Hammitzsch, A., Tallant, C., Fedorov, O., O'Mahony, A., Brennan, P.E., Hay, D.A., Martinez, F.O., Al-Mossawi, M.H., de Wit, J., Vecellio, M., et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc. Natl. Acad. Sci. USA 112 (2015), 10768–10773.
27. Haselmayer, P., Camps, M., Muzerelle, M., El Bawab, S., Waltzinger, C., Bruns, L., Abla, N., Polokoff, M.A., Jond-Necand, C., Gaudet, M., et al. Characterization of novel PI3Kdelta inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies. Front. Immunol., 5, 2014, 233.
28. Houck, K.A., Dix, D.J., Judson, R.S., Kavlock, R.J., Yang, J., Berg, E.L., Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen. 14 (2009), 1054–1066.
29. Kalinski, P., Regulation of immune responses by prostaglandin E2. J. Immunol. 188 (2012), 21–28.
30. Kim, B.H., Lee, Y.S., Kang, K.S., The mechanism of retinol-induced irritation and its application to anti-irritant development. Toxicol. Lett. 146 (2003), 65–73.
31. Kleinstreuer, N.C., Yang, J., Berg, E.L., Knudsen, T.B., Richard, A.M., Martin, M.T., Reif, D.M., Judson, R.S., Polokoff, M., Dix, D.J., et al. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat. Biotechnol. 32 (2014), 583–591.
32. Krayenbuhl, B.H., Elsner, P., Allergic and irritant contact dermatitis to calcipotriol. Am. J. Contact Dermat. 10 (1999), 78–80.
33. Kunkel, E.J., Dea, M., Ebens, A., Hytopoulos, E., Melrose, J., Nguyen, D., Ota, K.S., Plavec, I., Wang, Y., Watson, S.R., et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J 18 (2004), 1279–1281.
34. Kunkel, E.J., Plavec, I., Nguyen, D., Melrose, J., Rosler, E.S., Kao, L.T., Wang, Y., Hytopoulos, E., Bishop, A.C., Bateman, R., et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev. Technol 2 (2004), 431–441.
35. Lee, A., Thompson, J., Drug-induced Skin Reactions. Second Edition, 2006, Pharmaceutical Press.
36. Lee, C.E., Neuland, M.E., Teaford, H.G., Villacis, B.F., Dixon, P.S., Valtier, S., Yeh, C.H., Fournier, D.C., Charlesworth, E.N., Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals. J. Allergy Clin. Immunol. 89 (1992), 1010–1020.
37. Lee, C.W., Lin, Z.C., Hu, S.C., Chiang, Y.C., Hsu, L.F., Lin, Y.C., Lee, I.T., Tsai, M.H., Fang, J.Y., Urban particulate matter down-regulates filaggrin via COX2 expression/PGE2 production leading to skin barrier dysfunction. Sci. Rep., 6, 2016, 27995.
38. Martin, M.T., Dix, D.J., Judson, R.S., Kavlock, R.J., Reif, D.M., Richard, A.M., Rotroff, D.M., Romanov, S., Medvedev, A., Poltoratskaya, N., et al. Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem. Res. Toxicol. 23 (2010), 578–590.
39. McKenna, J.K., Leiferman, K.M., Dermatologic drug reactions. Immunol. Allergy Clin. North Am. 24 (2004), 399–423 vi.
40. Melton, A.C., Melrose, J., Alajoki, L., Privat, S., Cho, H., Brown, N., Plavec, A.M., Nguyen, D., Johnston, E.D., Yang, J., et al. Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation. PLoS One, 8, 2013, e58966.
41. Nish, S.A., Schenten, D., Wunderlich, F.T., Pope, S.D., Gao, Y., Hoshi, N., Yu, S., Yan, X., Lee, H.K., Pasman, L., et al. T cell-intrinsic role of IL-6 signaling in primary and memory responses. eLife, 3, 2014, e01949.
42. Noakes, R., The aryl hydrocarbon receptor: a review of its role in the physiology and pathology of the integument and its relationship to the tryptophan metabolism. Int. J. Tryptophan Res. 8 (2015), 7–18.
43. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32 (2000), 56–67.
44. Palanisamy, G.S., Marcek, J.M., Cappon, G.D., Whritenour, J., Shaffer, C.L., Brady, J.T., Houle, C., Drug-induced skin lesions in cynomolgus macaques treated with metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators. Toxicol. Pathol. 43 (2015), 995–1003.
45. Paromov, V., Suntres, Z., Smith, M., Stone, W.L., Sulfur mustard toxicity following dermal exposure: role of oxidative stress, and antioxidant therapy. J. Burns Wounds, 7, 2007, e7.
46. Pichler, W.J., Immune mechanism of drug hypersensitivity. Immunol. Allergy Clin. North Am. 24 (2004), 373–397 v-vi.
47. Quintana, F.J., Sherr, D.H., Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol. Rev. 65 (2013), 1148–1161.
48. Quiroz, J.A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., Santarelli, L., Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry 73 (2016), 675–684.
49. Raboisson, P., Breitholtz-Emanuelsson, A., Dahllof, H., Edwards, L., Heaton, W.L., Isaac, M., Jarvie, K., Kers, A., Minidis, A.B., Nordmark, A., et al. Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. Bioorg. Med. Chem. Lett. 22 (2012), 6974–6979.
50. Ravid, A., Shenker, O., Buchner-Maman, E., Rotem, C., Koren, R., Vitamin D induces cyclooxygenase 2 dependent prostaglandin E synthesis in HaCaT keratinocytes. J. Cell Physiol. 231 (2016), 837–843.
51. Rincon, M., Anguita, J., Nakamura, T., Fikrig, E., Flavell, R.A., Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J. Exp. Med. 185 (1997), 461–469.
52. Romanov, S., Medvedev, A., Gambarian, M., Poltoratskaya, N., Moeser, M., Medvedeva, L., Gambarian, M., Diatchenko, L., Makarov, S., Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat. Methods 5 (2008), 253–260.
53. Schafer, C.C., Wang, Y., Hough, K.P., Sawant, A., Grant, S.C., Thannickal, V.J., Zmijewski, J., Ponnazhagan, S., Deshane, J.S., Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget 7 (2016), 75407–75424.
54. Shah, F., Louise-May, S., Greene, N., Chemotypes sensitivity and predictivity of in vivo outcomes for cytotoxic assays in THLE and HepG2 cell lines. Bioorg. Med. Chem. Lett. 24 (2014), 2753–2757.
55. Shah, F., Leung, L., Barton, H.A., Will, Y., Rodrigues, A.D., Greene, N., Aleo, M.D., Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays. Toxicol. Sci. 147 (2015), 500–514.
56. Shenton, J.M., Teranishi, M., Abu-Asab, M.S., Yager, J.A., Uetrecht, J.P., Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. 16 (2003), 1078–1089.
57. Shiraishi, N., Nomura, T., Tanizaki, H., Nakajima, S., Narumiya, S., Miyachi, Y., Tokura, Y., Kabashima, K., Prostaglandin E2-EP3 axis in fine-tuning excessive skin inflammation by restricting dendritic cell functions. PLoS One, 8, 2013, e69599.
58. Stepan, A.F., Walker, D.P., Bauman, J., Price, D.A., Baillie, T.A., Kalgutkar, A.S., Aleo, M.D., Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24 (2011), 1345–1410.
59. Stephensen, C.B., Borowsky, A.D., Lloyd, K.C., Disruption of Rxra gene in thymocytes and T lymphocytes modestly alters lymphocyte frequencies, proliferation, survival and T helper type 1/type 2 balance. Immunology 121 (2007), 484–498.
60. Swedberg, M.D., Raboisson, P., AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J. Pharmacol. Exp. Ther. 350 (2014), 212–222.
61. Veldhoen, M., Hirota, K., Christensen, J., O'Garra, A., Stockinger, B., Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J. Exp. Med. 206 (2009), 43–49.
62. Wager, T.T., Hou, X., Verhoest, P.R., Villalobos, A., Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1 (2010), 435–449.
63. Waring, M.J., Arrowsmith, J., Leach, A.R., Leeson, P.D., Mandrell, S., Owen, R.M., Pairaudeau, G., Pennie, W.D., Pickett, S.D., Wang, J., et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14 (2015), 475–486.
64. Wormser, U., Langenbach, R., Peddada, S., Sintov, A., Brodsky, B., Nyska, A., Reduced sulfur mustard-induced skin toxicity in cyclooxygenase-2 knockout and celecoxib-treated mice. Toxicol. Appl. Pharmacol. 200 (2004), 40–47.
65. Xiao, R., Kanekura, T., Yoshida, N., Higashi, Y., Yan, K.L., Fukushige, T., Kanzaki, T., 9-cis-Retinoic acid exhibits antifibrotic activity via the induction of cyclooxygenase-2 expression and prostaglandin E2 production in scleroderma fibroblasts. Clin. Exp. Dermatol. 33 (2008), 484–490.
66. Xu, D., Kim, Y., Postelnek, J., Vu, M.D., Hu, D.Q., Liao, C., Bradshaw, M., Hsu, J., Zhang, J., Pashine, A., et al. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 341 (2012), 90–103.
67. Yao, C., Sakata, D., Esaki, Y., Li, Y., Matsuoka, T., Kuroiwa, K., Sugimoto, Y., Narumiya, S., Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15 (2009), 633–640.
68. Zerbib, F., Bruley des Varannes, S., Roman, S., Tutuian, R., Galmiche, J.P., Mion, F., Tack, J., Malfertheiner, P., Keywood, C., Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 33 (2011), 911–921.
69. Zhang, L., Balan, G., Barreiro, G., Boscoe, B.P., Chenard, L.K., Cianfrogna, J., Claffey, M.M., Chen, L., Coffman, K.J., Drozda, S.E., et al. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]-pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. J. Med. Chem. 57 (2014), 861–877.